Comment
. 2006 Sep-Oct;9(5):357; author reply 358.
doi: 10.1111/j.1524-4733.2006.00125.x.
Cost-effectiveness of olanzapine as a first-line treatment: a comment
- PMID: 16961554
- DOI: 10.1111/j.1524-4733.2006.00125.x
Item in Clipboard
Comment
Cost-effectiveness of olanzapine as a first-line treatment: a comment
Value Health.
2006 Sep-Oct.
Free article
No abstract available
Comment on
-
Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial.Value Health. 2006 Mar-Apr;9(2):77-89. doi: 10.1111/j.1524-4733.2006.00083.x. Value Health. 2006. PMID: 16626411 Clinical Trial.
Similar articles
-
Comments on cost analysis of risperidone versus olanzapine.J Clin Psychiatry. 2004 Jun;65(6):879-80; author reply 880. doi: 10.4088/jcp.v65n0622c. J Clin Psychiatry. 2004. PMID: 15291670 No abstract available.
-
Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia.J Eval Clin Pract. 2007 Jun;13(3):453-60. doi: 10.1111/j.1365-2753.2006.00782.x. J Eval Clin Pract. 2007. PMID: 17518814
-
Clinical trial-based cost-effectiveness analyses of antipsychotic use.Am J Psychiatry. 2006 Dec;163(12):2047-56. doi: 10.1176/appi.ajp.163.12.2047. Am J Psychiatry. 2006. PMID: 17151153 Review.
-
[Economic analyses of olanzapine in the treatment of schizophrenia and bipolar disorder].Actas Esp Psiquiatr. 2004 Sep-Oct;32(5):269-79. Actas Esp Psiquiatr. 2004. PMID: 15529211 Review. Spanish.
-
Olanzapine vs haloperidol for treatment of schizophrenia.JAMA. 2004 Mar 3;291(9):1065; author reply 1065-6. doi: 10.1001/jama.291.9.1065-a. JAMA. 2004. PMID: 14996767 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
